Dima Shulkin: Comparing HALP and PIV for Mortality Prediction in ACS
Dima Shulkin, Co-Founder and CTO at RobotDreams GmbH, shared a post on LinkedIn about a recent article by Azmi Eyiol, published in Journal of Clinical Medicine, adding:
“A new multicenter study in acute coronary syndrome puts two simple blood-based scores under the microscope: PIV, a combined immune-inflammation value, and HALP, a score built from hemoglobin, albumin, lymphocytes and platelets.
In 1.134 hospitalized patients, HALP predicted mortality better than PIV, with an AUROC of 0.722 versus 0.619, meaning it separated higher-risk from lower-risk patients more reliably.
The striking part is that this signal came from routine admission labs, not from a complex new test.”
Title: Pan-Immune-Inflammatory Value (PIV) and HALP Score as Independent Prognostic Indicators in Acute Coronary Syndrome Patients
Authors: Azmi Eyiol, Hatice Eyiol, Ahmet Yilmaz, Hasan Sari
Stay updated with Hemostasis Today.
-
Nov 15, 2026, 04:31Aakriti Gupta: Anticoagulation for Leaflet Thickening After TAVR
-
Nov 14, 2026, 23:57Jamie S. Y. Ho: Exploring the Mechanisms of Arterial Thrombosis and the Evolution of Antithrombotic Therapy
-
Nov 14, 2026, 23:53Jacopo Imberti: The Past, Present and Future of Arterial Thrombosis Research
-
Nov 14, 2026, 23:48Shrouk Ramadan: Joining the Editorial Review Board of Clinical and Applied Thrombosis and Hemostasis
-
Nov 14, 2026, 23:46Habib Bennaceur: Moving Towards Fewer Limitations for People Living With Haemophilia
-
Nov 14, 2026, 23:44Paul Healy: EU Approves Frehemgo for Haemophilia A
-
Nov 14, 2026, 23:43Mehak Trehan: ASH 2026 Benign Hematology – Ten Abstracts Through an Indian Lens
-
Nov 14, 2026, 23:33Felipe Magalhaes Furtado: Artificial Intelligence Advances PNH Clone Detection Through Machine Learning
-
Nov 14, 2026, 23:33Mona Alfaraj: International Pathology Day Promotes Education in Hemoglobinopathy Diagnostics